

LIQUIDATION ACCOUNTS
AND
PLAN OF DISTRIBUTION

CROWN LIQUIDATIONCO N.V. IN LIQUIDATIE
(formerly Centogene N.V.)
Trade Register No. 72822872

DATED 5 August 2026

1. Introduction

These liquidation accounts, including a plan of distribution (collectively, the "**Liquidation Accounts**"), have been prepared by the undersigned, **Peter Bauer**, acting in his capacity as liquidator (*vereffenaar*) (acting in such capacity, the "**Liquidator**") of **Crown LiquidationCo N.V. in liquidatie** (formerly Centogene N.V.), a public limited liability company (*naamloze vennootschap*) incorporated under the laws of the Netherlands, with trade register number 72822872 (the "**Company**"), in connection with the dissolution of the Company pursuant to Section 2:19(1)(a) of the Dutch Civil Code (*Burgerlijk Wetboek*, the "**DCC**"). These Liquidation Accounts describe the acts of liquidation performed by the Liquidator following the Dissolution Date (as defined below), the acts of liquidation still to be performed by the Liquidator as of the date of these Liquidation Accounts, the Company's expected remaining net assets following such acts, and the plan pursuant to which such remaining net assets shall be distributed to the Company's shareholders and holders of vested equity awards issued by the Company in respect of the Company's ordinary shares ("**Ordinary Shares**") underlying such equity awards ("**Award Holders**"), as if such respective Award Holders hold the Ordinary Shares underlying such equity awards, subject to deduction of any applicable exercise price in respect of such awards (collectively, the "**Entitled Holders**"). These Liquidation Accounts have been prepared and approved by the Liquidator and have been reviewed and approved by the supervisory board of the Company.

2. Background

The Company, at that time named Centogene N.V., was a publicly traded company incorporated under the laws of the Netherlands. The Ordinary Shares were listed on the Nasdaq Global Select Market ("**Nasdaq**") and, after the delisting of the Ordinary Shares from Nasdaq, were subsequently traded on an 'over-the-counter' market operating in the United States of America (the "**OTC**") under the ticker symbol CNTGF. The Company previously operated as a rare disease company, providing data-driven diagnostic, research, and pharmaceutical solutions for rare and neurodegenerative diseases.

Following an extensive strategic alternatives review process, on 12 November 2024, the Company entered into a share purchase agreement (the "**SPA**") with Charme IV, an Italian Fund represented by Charme Capital Partners Limited ("**Charme**") for the sale by the Company of (i) 100% of its shareholding in Centogene GmbH, the Company's main operating subsidiary at that time, and (ii) certain intra-group receivables, for an aggregate cash purchase price of EUR 8,717,906.80 and, as additional consideration, the assumption of certain debts of the Company (collectively, the "**Transaction**").

On 4 December 2024, the Company held an extraordinary general meeting (the "**EGM**") at which shareholders voted in favour of all voting items that were on the agenda of the EGM, including approval of the Transaction and the dissolution of the Company with effect from the moment immediately following the consummation of the Transaction ("**Closing**"). Closing occurred, and the Company's dissolution therefore became effective, on 13 March 2025 (the "**Dissolution Date**"), at which time the Company was also renamed Crown LiquidationCo N.V.

As from the Dissolution Date, the Company ceased all commercial operations, and the Liquidator commenced the liquidation of the Company's affairs. Since the Dissolution Date, the Company has not engaged in any activities other than those necessary or appropriate for the purpose of its liquidation.

3. Acts of Liquidation

3.1 General

From and after the Dissolution Date, the Liquidator has performed the following acts of liquidation:

- (1) Settlement of all outstanding debts and liabilities of the Company, including amounts owed to members and former members, as applicable, of the Company's management board and supervisory board, trade creditors, advisors, and service providers, in each case to the extent due and payable as at or prior to the date of these Liquidation Accounts;
- (2) Collection of all remaining receivables and other outstanding amounts owed to the Company or Centogene Switzerland AG ("**Centogene Switzerland**");
- (3) Termination or settlement of all remaining contractual arrangements and commercial agreements to which the Company or Centogene Switzerland was a party;
- (4) Completion of the transfer of the Company's interest in Genomics Innovations Company Ltd. in accordance with the terms of the Transaction Agreements;
- (5) Successfully defending the Company against legal claims initiated by certain shareholders of the Company before the Dutch Enterprise Court of the Amsterdam Court of Appeals;
- (6) Reaching a settlement with a former member of the Company's management board and settling the Company's obligations thereunder;
- (7) Coordination with the Financial Industry Regulatory Authority ("**FINRA**") and OTC Markets Group in connection with the cessation of trading of the Ordinary Shares on the OTC, including notification to the Company's transfer agent, Equiniti Trust Company, LLC ("**Equiniti**"), in accordance with applicable requirements;
- (8) Closure or consolidation of bank accounts and management of remaining cash balances of the Company and Centogene Switzerland; and
- (9) Such further administrative, regulatory, and operational steps as were necessary or appropriate to finalize the liquidation of the Company and Centogene Switzerland.

Following the completion of the foregoing acts of liquidation, (i) the Liquidator has made reasonable provision for all known and reasonably foreseeable costs, expenses, debts and other liabilities and obligations of the Company that may arise between the date of these Liquidation Accounts and the finalization of the Company's liquidation (collectively, the "**Anticipated Costs**") and (ii) the Liquidator has caused payment of the First Distribution (as defined below) as further described in chapter 3.1.

The following acts of liquidation remain in progress and shall be completed before the Second Distribution (as defined below) (the "**Ongoing Acts of Liquidation**"):

- (1) Completion of the liquidation of Centogene Switzerland;
- (2) Settlement of all remaining tax obligations of the Company and Centogene Switzerland and filing of all required tax returns and regulatory submissions with the competent tax authorities in connection with the liquidation of the Company and Centogene Switzerland; and

- (3) Settlement of all remaining debts and liabilities of the Company, including amounts owed to members and former members, as applicable, of the Company's management board and supervisory board, trade creditors, advisors, and service providers, in each case to the extent incurred between the date of these Liquidation Accounts and the finalization of the formal liquidation of the Company.

The estimated aggregate costs associated with the Ongoing Acts of Liquidation have been taken into account by the Liquidator in determining the Anticipated Costs. The Liquidator expects the Anticipated Costs to range between \$473,901 and \$635,632, but no assurances can be given about the definitive amount of the Anticipated Costs that may actually be incurred by the Company.

3.2 First Distribution and Cessation of Trading

Furthermore, the Liquidator concluded that the Company's financial position justified making an advance distribution of liquidation proceeds (*uitkering bij voorbaat*) to the relevant Entitled Holders within the meaning of Section 2:23b(6) of the DCC in the aggregate amount of \$3,066,167 (the "**First Distribution**"). On 27 May 2026, the Liquidator resolved to make the First Distribution, determined that the record date for the First Distribution would be 27 May 2026 (the "**First Record Date**"), and caused payment of the First Distribution on a pro rata basis to the Entitled Holders as of the First Record Date through Equiniti, acting as transfer agent in respect of Ordinary Shares, and through Centogene GmbH (the "**Financial Service Provider**"), acting as payroll administrator in respect of Award Holders (assuming, on a pro forma basis, exercise and settlement in full of all vested equity awards issued by the Company in respect of the Ordinary Shares and subject to deduction of any applicable exercise price in respect of such awards).

Prior to making the First Distribution, the Company has notified FINRA and OTC Markets Group of the First Distribution. The First Record Date was the date on which trading in the Ordinary Shares ceased on the OTC, as confirmed by FINRA.

3.3 Filing and Announcement of Liquidation Accounts

Promptly following the date of these Liquidation Accounts, the Liquidator shall cause these Liquidation Accounts to be filed with the Dutch trade register and at the Company's office address, and the Liquidator shall cause the publication of such filing in a Dutch daily newspaper with national distribution, in accordance with the relevant requirements under Dutch law. Creditors may oppose these Liquidation Accounts for a period of two (2) months following such publication and, in case of any such opposition, the Liquidator shall give notice thereof in the same manner in which the filing of these Liquidation Accounts was published.

During this period, the Liquidator shall continue to progress the completion of the Ongoing Acts of Liquidation.

Once the Ongoing Acts of Liquidation have been completed and provided that no creditor opposition has been lodged in a timely manner and in accordance with Dutch law, the Liquidator shall proceed with payment of all at that time remaining net assets of the Company as described in chapter 4.

4. Liquidation Proceeds and Plan of Distribution

4.1 Liquidation Proceeds

Following the completion of the acts of liquidation, including the Ongoing Acts of Liquidation, described in chapter 3.1 and the payment of the First Distribution described in chapter 3.2, and

taking into account the Anticipated Costs, the Liquidator currently expects the Company's remaining net assets available for distribution to the relevant Entitled Holders (the "**Liquidation Proceeds**") to range between \$1,802,009 and \$1,297,964.

However, as the exact amount of Liquidation Proceeds will depend on the exact amount of the Anticipated Costs, potential unforeseen claims, costs, expenses, debts and other liabilities and obligations of the Company that may arise after the date of these Liquidation Accounts and/or potential unforeseen entitlements of the Company to cash, interest or other assets that might arise after the date of these Liquidation Accounts, as well as fluctuating exchange rates, the definitive amount of Liquidation Proceeds (which may therefore be higher or lower than the amounts reflected above, and which may even become nil) distributable to the relevant Entitled Holders shall be determined by the Liquidator only shortly before such distribution is made. The Liquidator shall provide Entitled Holders with reasonable notice of the definitive amount of the Liquidation Proceeds, as well as the record date and payment date of the distribution thereof (the "**Second Distribution**") via the Company's investor website.

4.2 Plan of Distribution

The Second Distribution shall be made to the Entitled Holders as of the record date determined by the Liquidator for the Second Distribution, on a pro rata basis (assuming, on a pro forma basis, exercise and settlement in full of all vested equity awards issued by the Company in respect of the Ordinary Shares and subject to deduction of any applicable exercise price in respect of such awards). The Second Distribution shall be paid through Equiniti, acting as transfer agent in respect of Ordinary Shares, and through the Financial Service Provider, acting as payroll administrator in respect of Award Holders, in accordance with the following mechanics:

- (1) **Direct Holders:** Entitled Holders as at the record date of the Second Distribution who hold Ordinary Shares directly through Equiniti's register (the "**Equiniti Register**") shall receive their distribution by bank check dispatched via the U.S. Postal Service or, at the Company's discretion, by overnight courier for addresses outside the United States of America, including Germany.
- (2) **Broker-Held Shares (DTC/Cede & Co.):** Entitled Holders as at the record date of the Second Distribution who hold Ordinary Shares through brokers or nominees via The Depository Trust Company ("**DTC**") or Cede & Co. shall receive their distribution through the standard DTC payment mechanism. Equiniti shall remit the applicable distribution amount to the relevant broker or nominee via DTC, and such broker or nominee shall in turn credit the accounts of the beneficial holders of the relevant Ordinary Shares. The Company shall not be required to make payment directly to such beneficial holders.
- (3) **Award Holders:** Award Holders as at the record date of the Second Distribution shall receive their distribution via payroll, processed through the Financial Service Provider. The Company shall transfer the aggregate amount due to Award Holders to the Financial Service Provider, which shall in turn process the individual distributions to each Award Holder via payroll in accordance with applicable law. The Company shall confirm the individual entitlement of each Award Holder, including the amount and timing of payment, with the Financial Service Provider prior to the payment of the Second Distribution.


4.3 Abandoned Property

The Company shall remit the entire definitive amount of the Second Distribution to Equiniti, except for the amount payable to Award Holders, which will be transferred to the Financial Service Provider as set forth above, and it has done the same with respect to the First Distribution. In the event that any part of the First Distribution and/or the Second Distribution cannot be paid to the

relevant Entitled Holders (the “**Unclaimed Amount**”) - whether because they cannot be located, the Company does not have (or otherwise has failed to provide) the required correct mailing address or other requisite information, or for any other reason - such Unclaimed Amount shall be kept by Equiniti in its capacity as transfer agent for the sole and exclusive benefit and account of the relevant Entitled Holder(s) until such time as payment can be made to such Entitled Holder(s). In such case, Equiniti shall continue to hold such Unclaimed Amount for the sole and exclusive benefit and account of the relevant Entitled Holder(s) and shall use reasonable efforts to locate and effect payment to such Entitled Holder(s) in accordance with its standard procedures. To the extent any Unclaimed Amount remains unclaimed and unpaid following completion of the Company's liquidation, such Unclaimed Amount shall be handled in accordance with applicable U.S. state unclaimed property and escheatment laws, as administered by Equiniti. Under no circumstances will the Company have any claim on any part of any Unclaimed Amount.

SIGNATURE PAGE

Liquidation Accounts and Plan of Distribution of Crown LiquidationCo N.V. in liquidatie

Signiert von:

5C01017570104C9...

Name: Peter Bauer

Title: Liquidator (vereffenaar)